| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.1 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.078 | 0.1 |